Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Evaluation and Request for Credit Form

Evaluation and Request for Credit Form SUPPLEMENT 9888 Journal Supplement Molecular Analysis-Based Treatment Strategies for the Management of Non-Small Cell Lung Cancer Authors: Howard West, MD; Rogerio Lilenbaum, MD; David Harpole, MD; Antoinette Wozniak, MD; and Lecia Sequist, MD, MPH Release date: August 25, 2009 Expiration date: August 24, 2010 Participant History My preferred educational format is: Number of CME-accredited articles read annually: Symposium/conference/workshop CD-ROM/DVD Podcast 0-5 6-10 11-15 16-20 >20 Online activity Monograph/journal supplement PDA CME Satellite broadcast Educational Objectives Indicate on a scale from 1 to 5 the extent to which you agree that the activity met the following educational objectives. Please use the following codes to evaluate: 1 = Strongly Disagree 2 = Disagree 3 = Neutral 4 = Agree 5 = Strongly Agree Describe the rationale for using molecular markers to individualize treatment for patients with NSCLC. 1 2 3 4 5 Evaluate the use of molecular profiling to predict clinical outcomes in the adjuvant setting for patients with NSCLC. 1 2 3 4 5 Discuss the use of predictive markers to direct selection of chemotherapeutic agents for the treatment of NSCLC. 1 2 3 4 5 Discuss the use of molecular markers to refine the use of targeted agents for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Evaluation and Request for Credit Form

Journal of Thoracic Oncology , Volume 4 – Sep 1, 2009

Loading next page...
 
/lp/wolters-kluwer-health/evaluation-and-request-for-credit-form-BQrpWUF01S

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

SUPPLEMENT 9888 Journal Supplement Molecular Analysis-Based Treatment Strategies for the Management of Non-Small Cell Lung Cancer Authors: Howard West, MD; Rogerio Lilenbaum, MD; David Harpole, MD; Antoinette Wozniak, MD; and Lecia Sequist, MD, MPH Release date: August 25, 2009 Expiration date: August 24, 2010 Participant History My preferred educational format is: Number of CME-accredited articles read annually: Symposium/conference/workshop CD-ROM/DVD Podcast 0-5 6-10 11-15 16-20 >20 Online activity Monograph/journal supplement PDA CME Satellite broadcast Educational Objectives Indicate on a scale from 1 to 5 the extent to which you agree that the activity met the following educational objectives. Please use the following codes to evaluate: 1 = Strongly Disagree 2 = Disagree 3 = Neutral 4 = Agree 5 = Strongly Agree Describe the rationale for using molecular markers to individualize treatment for patients with NSCLC. 1 2 3 4 5 Evaluate the use of molecular profiling to predict clinical outcomes in the adjuvant setting for patients with NSCLC. 1 2 3 4 5 Discuss the use of predictive markers to direct selection of chemotherapeutic agents for the treatment of NSCLC. 1 2 3 4 5 Discuss the use of molecular markers to refine the use of targeted agents for

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Sep 1, 2009

There are no references for this article.